Navigation Links
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
Date:7/14/2014

nd targeted indication is glioblastoma, a form of brain cancer with high unmet need. GNSZ's drug does not need to cross the brain barrier.
  • Both indications require smaller clinical studies and offer fast track to FDA approval. 
  • Phase II clinical trial in glioblastoma was initiated in Q1 2014.
  • GNSZ's patented technology platform has additional applications in other large cancer indications as well as imaging applications.
  • GenSpera's corporate strategy is to "de-risk" its products and thus harvest significant value via the development of drug compounds through Phase II clinical trials. GenSpera's strategy is to then monetize its efforts after conducting Phase II trials, through exit strategies, i.e., licensing or sale to "Big Pharma" without incurring the time, cost and risk of building a pharmaceutical marketing and sales organization. GNSZ has signed a number of NDA's with mid-size and "Big Pharmas". Drug development is increasingly being relegated to "junior companies" with "Big Pharma" willing to acquire the technology or drug after it has been de-risked. For example, in 2010, companies with Phase II assets were acquired at a mean price of $85 million with milestone payments of $55.2 million, and the potential of a double digit royalty percentage. Cougar Biotech, a former Bulletin-Board listed company was acquired by Johnson & Johnson in 2009 for $970M in cash for their prostate cancer drug (ZYTIGA™) which received FDA approval in April 2011. 
  • GenSpera has a robust global IP position, with a portfolio of filed and granted patents covering 12ADT and other derivatives of Thapsigargin, peptide "masking/targeting" sequences and their prodrug conjugates. The patents are owned by GenSpera with no royalties or milestone payments payable to any third party.
  • GenSpera has an experienced and well-seasoned management and scientific team. Craig Dionne, PhD, CEO, has ext
    '/>"/>

  • SOURCE GenSpera, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. CVS Caremark Corporation Announces Quarterly Dividend
    2. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
    3. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
    4. Volcano Corporation Announces Preliminary Fourth Quarter 2013 Revenues; Year-Over-Year Annual Revenues Increase Eight Percent On A Constant Currency Basis
    5. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
    6. Heska Corporation to Present at the Sidoti Semi-Annual Micro-Cap Conference
    7. Ramon Martinez Named President of Comprehensive Care Corporation and Elected to the Companys Board of Directors
    8. Dynasil Corporation of America Reports Fiscal Year 2013 Financial Results
    9. Ormco Corporation Files Appeal to the Federal Court Against Ortho Classic H4 Bracket Patent Infringement
    10. EPGL Technology Selected by Major Corporation for Development
    11. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
    (Date:9/22/2014)... Sept. 22, 2014 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ... developing premium quality medical marijuana products, is pleased to ... ("Thunderbird"), has signed a definitive lease agreement for a ... BC.  The facility has 28,966 square feet of floor ... feet of mezzanine space for a total of approximately ...
    (Date:9/22/2014)... CENTER VALLEY, Pa. , Sept. 22, 2014 ... and delivering innovative solutions for medical and surgical ... has reached a deal with Munich ... distributor of Kick ® Navigation. This agreement ... maintain distribution for cross-disciplinary U.S. sales and all ...
    Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
    ... SAN DIEGO, Nov. 5 Conatus Pharmaceuticals Inc. ... CTS-1027 in,multiple models of hepatitis, an inflammatory liver ... today at the American Association for,the Study of ... significantly reduced liver damage following oral,administration in four ...
    ... Meeting of Connective Tissue Oncology, Society held in Seattle, ... perifosine as a single agent in patients with ... chemo-insensitive sarcomas, ... today announced that preliminary data demonstrating the,tolerability and clinical activity of ...
    Cached Medicine Technology:Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6
    (Date:9/22/2014)... September 22, 2014 WHO: LiveOps, ... and customer service solutions. , WHAT: The 10th ... on customer care for the connected consumer. Constant ... to offer new challenges and opportunities for customer ... attendees identify best practices, network and learn from ...
    (Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
    (Date:9/22/2014)... Tara Haelle ... News) -- Measuring how quickly a child,s brain processes ... to a new study. Observing children,s brainwaves ... currently possible, the study authors reported. "The finding ... is associated with autism severity is hugely promising," said ...
    (Date:9/22/2014)... September 22, 2014 The “ Ztylus ” ... Tech Report , which reviews and features the latest technology ... of NewsWatch and technology expert, conducted the review and shared ... snap-in lens kit that gives users four lens options for ... part of its monthly Tech Report, which reviews and features ...
    (Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
    Breaking Medicine News(10 mins):Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
    ... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... receive fewer blood transfusions do just as well as those ... of blood transfusions varies widely among U.S. hospitals. The ... Journal of the American Medical Association . In ...
    ... murine leukemia virusrelated virus (XMRV) has been the subject ... conflicting reports have created an unclear picture of XMRV,s ... in the November 15 issue of The Journal ... supports a possible link between XMRV and prostate cancer ...
    ... molecule they designed can block activation of a gene in ... those cancer cells to survive chemotherapy. Without the ... to be protected from the toxic effects of chemotherapy drugs. ... protecting the cells, the research suggests. As a result, more ...
    ... By Amanda Gardner HealthDay Reporter , TUESDAY, Oct. ... cancer patients treated with bisphosphonate drugs such as Aredia or ... be at higher risk for the irregular heartbeat known as ... atrial fibrillation, the upper chambers of the heart beat chaotically, ...
    ... results of a large Phase-III clinical trial have shown ... with a hard-to-treat group of rare cancers that affect ... the European Society for Medical Oncology (ESMO), Dr Marianne ... everolimus improved progression-free survival by 5.1 months in patients ...
    ... of breast cancer can lead some women to wonder if ... of more than 85,000 postmenopausal women, published in BioMed Central,s ... regular physical activity, maintaining a healthy weight, and drinking less ... a family history of the disease. The University of ...
    Cached Medicine News:Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 2Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2
    For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
    The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
    ... SR™ Hand Implant System utilizes the same ... joint replacements. The SR™ Hand Implant ... other prostheses including minimal bone resection, surface ... articular surfaces, retention and/or repositioning of the ...
    ... the hand can make simple motions such ... key painful, if not impossible. The Avanta ... the disabling effects of this disease. ... and joint-specific design features these implants offer ...
    Medicine Products: